Cassava Sciences, Inc. ($SAVA) Stock Forecast: Up 5.8% Today

What is Cassava Sciences, Inc.?

Filana Therapeutics (NASDAQ:FLNA) is a biotech company specializing in developing filamin A-modulating therapies for central nervous system disorders, particularly TSC-related epilepsy, and experienced a significant bullish movement in the market today.

Why is Cassava Sciences, Inc. going up?

SAVA stock is up 5.8% on Mar 13, 2026 13:51

• The company surpassed earnings estimates by $0.04 EPS, yet the stock price remained at $2.38, with the market showing a subdued reaction to this positive performance.
• Filana Therapeutics (FLNA)'s rebranding and strategic shift towards addressing high-unmet-need epilepsy conditions potentially attracted investor attention, influencing the stock's upward trend.
• Increased institutional investment, including a notable stake raise by Marshall Wace LLP, likely enhanced investor confidence in the company's new focus and future outlook, contributing to the positive trajectory of the stock.
• Despite facing financial hurdles and mixed analyst evaluations, the market appears cautiously upbeat about Filana Therapeutics (FLNA), as evidenced by today's bullish movement.

SAVA Price Chart

SAVA Technical Analysis

SAVA News

Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS

Cassava Sciences (NASDAQ:SAVA) announced its earnings results, reporting an adjusted EPS of ($0.26), which surpassed the consensus estimate of ($0.30) by $0.04. Despite beating estimates, the company's shares remained flat at $2.38, and Wall Street maintains a "Reduce" rating with an average target price of $2.00. Institutional investment in Cassava Sciences has increased, with Marshall Wace LLP significantly raising its stake, bringing overall institutional ownership to 38.05%.

https://www.marketbeat.com/instant-alerts/cassava-sciences-nasdaqsava-posts-earnings-results-beats-estimates-by-004-eps-2026-03-12/

Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker

Cassava Sciences has rebranded as Filana Therapeutics, Inc. and will trade under the new ticker FLNA on the Nasdaq Capital Market starting March 11, 2026. This change reflects the company's refined strategic focus on developing filamin A–modulating therapies for central nervous system disorders, particularly tuberous sclerosis complex (TSC)-related epilepsy. The rebranding aims to sharpen its market positioning in high-unmet-need epilepsy indications, potentially attracting focused investor interest despite ongoing financial challenges and a "Hold" rating from analysts.

https://www.tipranks.com/news/company-announcements/cassava-sciences-rebrands-as-filana-therapeutics-updates-ticker

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

Cassava Sciences has officially changed its name to Filana Therapeutics, Inc., effective March 10, 2026. This rebranding reflects the company's focus on developing novel medicines that modulate the filamin A protein, particularly for treating TSC-related epilepsy. Filana Therapeutics will begin trading under the ticker symbol "FLNA" on March 11, 2026.

https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-announces-name-change-filana-therapeutics-inc

Trending Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.2% Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 6.0% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Down 5.2% Today

Silver ($XAG) Commodity Forecast: Down 5.3% Today

Lamb Weston Holdings Inc. ($LW) Stock Forecast: Down 5.4% Today

CDW Corporation ($CDW) Stock Forecast: Down 5.0% Today

Southwest Airlines Company ($LUV) Stock Forecast: Down 5.3% Today

Workday Inc. ($WDAY) Stock Forecast: Down 5.0% Today

General Dynamics Corporation ($GD) Stock Forecast: Down 0.6% Today

Lockheed Martin Corporation ($LMT) Stock Forecast: Down 2.6% Today

Cassava Sciences, Inc. Price History

14.00.2026 - SAVA Stock was up 5.6%

• Despite disappointing Phase 3 trial results for simufilam in Alzheimer’s disease, Cassava Sciences experienced a strong bullish movement.
• The announcement of pivoting towards developing simufilam for TSC-related epilepsy might have sparked investor optimism and interest in the company's future prospects.
• The increased volume of call options being bought, along with insider buying and institutional investment, could indicate a belief in the potential success of the new development direction despite the challenges faced by the company.
• The stock price increase could also be influenced by short-term speculative trading rather than a reflection of the company's long-term outlook.

24.01.2026 - SAVA Stock was up 10.7%

• The closure of the investigation into Cassava Sciences has brought relief to investors, leading to a bullish movement in the stock.
• The decision to scrap the development of simufilam for Alzheimer's and focus on tuberous sclerosis complex-related epilepsy may have positively influenced market sentiment.
• Resolving legal uncertainties and moving forward with a new therapeutic direction could be seen as a strategic and positive development for Cassava Sciences, driving investor confidence and pushing the stock price higher.

21.00.2026 - SAVA Stock was up 6.3%

• The upward movement in SAVA today may be linked to positive developments or speculation surrounding the advancement of its Alzheimer's drug, simufilam.
• Investors could be reacting to recent updates on the clinical trials or regulatory approval process, leading to a rise in the stock price.
• The risky nature of Cassava Sciences might also be attracting investors seeking potential high returns despite the volatility.

13.02.2026 - SAVA Stock was up 5.8%

• The company surpassed earnings estimates by $0.04 EPS, yet the stock price remained at $2.38, with the market showing a subdued reaction to this positive performance.
• Filana Therapeutics (FLNA)'s rebranding and strategic shift towards addressing high-unmet-need epilepsy conditions potentially attracted investor attention, influencing the stock's upward trend.
• Increased institutional investment, including a notable stake raise by Marshall Wace LLP, likely enhanced investor confidence in the company's new focus and future outlook, contributing to the positive trajectory of the stock.
• Despite facing financial hurdles and mixed analyst evaluations, the market appears cautiously upbeat about Filana Therapeutics (FLNA), as evidenced by today's bullish movement.

22.11.2025 - SAVA Stock was up 6.3%

• SAVA's stock rose despite encountering a setback with an FDA clinical hold on a proposed trial for Simufilam in TSC-related epilepsy.
• Investor optimism may stem from expectations that the company can meet FDA requirements for the trial, prompting the market's bullish response.
• Speculation on Cassava Sciences' future performance in neurology research could be driving the positive market sentiment.
• The bullish movement reflects investor confidence in the company's ability to navigate regulatory hurdles and advance its research endeavors in neurological disorders.

06.01.2026 - SAVA Stock was up 5.5%

• The positive movement in SAVA stock today could be linked to an upgrade from a prominent financial analysis source, potentially boosting investor confidence.
• A notable rise in CEO Richard Barry's ownership stake by more than 10% might reflect optimism and faith in the company's future.
• Diverse analyst viewpoints aside, the recent insider activity and potential advancements in Alzheimer's disease treatments may have influenced the upward trend in the stock value.

16.00.2026 - SAVA Stock was down 5.2%

• Cassava Sciences unveiled the outcomes of its Phase 3 clinical trials for simufilam targeting Alzheimer's disease, indicating that the drug fell short of its primary, secondary, and exploratory objectives. As a result, the Alzheimer's program was terminated.
• Despite this setback, Cassava Sciences is redirecting its efforts towards developing simufilam for epilepsy related to tuberous sclerosis complex (TSC), although it is encountering obstacles like a recent FDA clinical hold on its proposed trial for this new use.
• The company is grappling with financial difficulties, marked by substantial net losses and a settlement for a securities class action lawsuit. These challenges likely contributed to the recent market downturn as investors respond to the uncertainties surrounding Cassava Sciences' future in the pharmaceutical domain.

23.11.2025 - SAVA Stock was down 5.3%

• SAVA stock plummeted by 24% due to the FDA placing a full clinical hold on its proposed proof-of-concept trial for simufilam in TSC-related epilepsy, leading to investor concerns and a bearish sentiment.
• The announcement of a $31.25 million settlement to end a securities class action lawsuit from 2021, although not an admission of fault, might have added to the negative sentiment surrounding the stock.
• With setbacks in previous trials for simufilam in Alzheimer's disease and now in epilepsy, investors are wary of the company's ability to successfully develop and bring its treatments to market, contributing to the bearish movement in the stock price.
• The delays in trial initiation and the FDA's requirements for additional information and protocol modifications have raised uncertainties about the future timeline and success of simufilam, further impacting the stock's performance negatively.

05.02.2026 - SAVA Stock was down 5.6%

• Analysts expect Cassava Sciences (SAVA) to report a quarterly loss per share, indicating a negative forecast.
• The company's financial statements display worrisome metrics including a negative EBITDA, free cash flow, and net income, highlighting financial challenges.
• Recent SEC filings have disclosed significant events like an FDA clinical hold on a trial, potentially impacting investor trust in the company's pipeline.
• The anticipated earnings loss mirrors the prevailing negative sentiment surrounding the stock, influencing today's bearish market activity.

30.11.2025 - SAVA Stock was down 6.3%

• The bearish movement observed in SAVA stock today might be linked to the resolution of a consolidated securities class action lawsuit for $31.25 million. While not admitting fault, this settlement could have raised concerns among investors regarding the company's corporate governance and legal matters.
• The recent FDA clinical hold on Cassava Sciences' proposed simufilam clinical trial for TSC-related epilepsy may have also contributed to the negative sentiment. Investors could be anxious about the delays in advancing this significant drug candidate.
• Shareholder engagement and discussions surrounding potential corporate governance adjustments, as brought up by Halper Sadeh LLC, may be heightening the uncertainty surrounding the stock. Investors might be exercising caution concerning the company's upcoming policies and decision-making procedures.
• Despite the obstacles, the resolution of the investor lawsuit and the company's concentration on advancing simufilam for TSC-related epilepsy could provide some hope for the future. Nevertheless, the stock could face fluctuations as investors analyze the consequences of these recent occurrences.

26.00.2026 - SAVA Stock was down 5.4%

• SAVA was downgraded to a "sell" rating, potentially sparking a bearish sentiment among investors.
• Despite surpassing earnings estimates, the overall consensus rating remains "Reduce" with a low average price target of $2.00, possibly contributing to the prevailing negative sentiment.
• The mixed signals from the earnings performance versus the "sell" rating could have resulted in uncertainty, fueling the significant bearish trend observed in SAVA's stock price.

11.02.2026 - SAVA Stock was up 5.8%

• The bullish movement in SAVA stock today could be attributed to the company's strategic rebranding as Filana Therapeutics, Inc., signaling a shift towards a more focused approach in developing treatments for high-unmet-need epilepsy indications.
• Investors may view this rebranding as a positive step towards addressing specific medical needs, potentially attracting increased investor interest in the company's future prospects.
• The market's positive reaction to the name change and refined strategic focus suggests that investors are optimistic about Filana Therapeutics' potential in the field of central nervous system disorders, particularly TSC-related epilepsy.